Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
Fusion Pharma is using targeted alpha therapeutics to improve the safety of radiopharmaceuticals.
Fusion Pharmaceuticals was founded in 2014 by Dr. John Valliant. The company is headquartered in Hamilton, Ontario, Canada, with an office in Boston, Massachusetts.
Fusion exploits its unique expertise in linking medical isotopes to targeting molecules to create novel therapeutics.
Fusion created a proprietary linker to connect cancer-seeking molecules and alpha emitting medical isotopes. The Fast-Clear™ linker was specifically engineered to improve the safety of radiopharmaceuticals by helping the drug clear from normal, healthy tissues.
Fusion’s proprietary Fast-Clear™ Linker Technology Platform promotes the rapid excretion of medical isotopes that are not specifically bound to cancer cells. In addition to its lead program, FPI-1434, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.
Fusion is backed by Varian, OrbiMed, Perceptive Advisors, Healthcap, Pivotal bioVenture Partners, Rock Springs Capital, Adams Street Partners and others. The company raised $105M in Series B round in April 2019. This brings Fusion's total funding to $170.9M to date.